Home » CUBIST PHARMACEUTICALS 'OUTPERFORM,' TARGET PRICE RAISED
CUBIST PHARMACEUTICALS 'OUTPERFORM,' TARGET PRICE RAISED
Analysts at RBC Capital Markets reiterate their "outperform" rating on Cubist Pharmaceuticals. The target price has been raised from $25 to $33.
Newratings
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May